Polymorphic variations in androgen-regulatory genes may contribute to an increased susceptibility [39], and recent GWAS studies confirm correlations of biosynthesis and metabolic pathway variants, such as CYP17A1 and CYP3A4, with prostate cancer risk [40,41]. The gene discussed is CYP3A4; the disease is Familial prostate cancer.